Evidence map›Paper›PMID 42048449›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Computational design of HLA class I superbinders for broad T cell immunogenicity.

Elinor Peer, Liel Cohen-Lavi, Alessandro Sette, John Sidney, Tomer Hertz

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Elinor Peer *Department of Microbiology Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.ORCID 0009-0009-2604-382X
Liel Cohen-Lavi *Department of Industrial Engineering and Management, Faculty of Engineering, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.ORCID 0000-0001-6909-4779
Alessandro SetteCenter for Vaccine Innovation, La Jolla Institute for Immunology, San Diego, CA 92037.
John SidneyCenter for Vaccine Innovation, La Jolla Institute for Immunology, San Diego, CA 92037.ORCID 0000-0002-0987-405X
Tomer HertzDepartment of Microbiology Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.ORCID 0000-0002-0561-1578

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human leukocyte antigen (HLA) class I molecules are highly polymorphic, restricting peptide binding to narrow sequence subsets. Designing peptides that bind multiple HLA supertypes-termed superbinders-offers a promising strategy for broad-spectrum T cell vaccines and immunotherapies. Here, we present superHLA, a computational framework that combines Markov Chain Monte Carlo optimization with state-of-the-art major histocompatibility complex binding predictors to design synthetic 9-mer peptides with broad HLA-binding profiles. Using superHLA, we generated over 190,000 candidate superbinders predicted to bind 8 to 12 HLA class I alleles across distinct supertypes. A multitier filtering pipeline-incorporating sequence clustering, synthesis feasibility, cross-predictor validation, and self-peptidome exclusion-yielded a final panel of 100 peptides for experimental testing. Of these, 21 bound 4 to 9 supertypes in vitro. Superbinders displayed distinct anchor residue preferences and showed minimal similarity to human peptides. These results suggest that HLA superbinders are more abundant than previously recognized and can be rationally designed at scale. This approach supports development of pan-HLA immunogens with broad population coverage and may inform applications in vaccine research, neoantigen discovery, and immunotherapy.

Indexed as

Computational BiologyHistocompatibility Antigens Class IPeptidesT-LymphocytesHumansImmunoinformaticsMarkov ChainsMonte Carlo MethodProtein BindingHistocompatibility Antigens Class IPeptidescomputational immunologyHLA binding predictionimmunoinformatics

Identifiers

PMID42048449
PMCPMC13142983

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.